Abstract:The article “The Role of CARD9 in Metabolic Diseases”, written by Cheng TIAN, Ya-li TUO, Yi LU, Chuan-rui XU, Ming XIANG, was originally published electronically on the publisher’s internet portal on May 2020 without open access. With the author(s)’ decision to opt for Open Choice, the copyright of the article is changed to © The Author(s) 2020 and the article is forthwith distributed under a Creative Commons Attribution 4.0 International License ( https://creativecommons.org/licenses/by/4.0/ ), which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The original article has been corrected.

Erratum to: CAR T Cell Therapy for Hematological Malignancies

Erratum to: The Role of CARD9 in Metabolic Diseases

Circ0021205 Aggravates the Progression of Non-Small Cell Lung Cancer by Targeting Mirna-16-5p/vegfa

Erratum: Evaluation of the clinicopathologic features of diffuse large B cell lymphoma after CD19-targeted CAR T-cell therapy emphasizing the potential diagnostic pitfalls.

Erratum to: Transmission risk of patients with COVID-19 meeting discharge criteria should be interpreted with caution (Journal of Zhejiang University-SCIENCE B, (2020), 21, 5, (408-410), 10.1631/jzus.B2000117)

Correction Notice: Inferior Outcomes of EU Versus US Patients Treated With CD19 CAR-T for Relapsed/Refractory Large B-cell Lymphoma: Association With Differences in Tumor Burden, Systemic Inflammation, Bridging Therapy Utilization, and CAR-T Product Use

Correction To: Therapeutic Efficacy, Pharmacokinetic Profiles, and Toxicological Activities of Humanized Antibody-Drug Conjugate Zt/g4-MMAE Targeting RON Receptor Tyrosine Kinase for Cancer Therapy

Correction: Unique CDR3 Epitope Targeting by CAR-T Cells is a Viable Approach for Treating T-cell Malignancies

Erratum To: Transmission Risk of Patients with COVID-19 Meeting Discharge Criteria Should Be Interpreted with Caution

Erratum to: Fluorescent glycan nanoparticle-based FACS assays for the identification of genuine drug-resistant cancer cells with differentiation potential

Erratum: Hepatic Carcinoma with Indolent T-lymphoblastic Proliferation (It-Lbp).

Erratum: the FoxO–BNIP3 Axis Exerts a Unique Regulation of Mtorc1 and Cell Survival under Energy Stress

Erratum: Author Correction to "Tumor-Microenvironment Activated Duplex Genome-Editing Nanoprodrug for Sensitized Near-Infrared Titania Phototherapy" [acta Pharm Sin B (2022) 4224-4234].

Erratum to 'Evolution and genotypic characteristics of small cell lung cancer transformation in non-small cell lung carcinomas' [Journal of the National Cancer Center, 1 (2021), 4: 153-162]

Blood TfR+ exosomes separated by a pH-responsive method deliver chemotherapeutics for tumor therapy: Erratum

Erratum to: A novel GSH responsive poly(alpha-lipoic acid) nanocarrier bonding with the honokiol-DMXAA conjugate for combination therapy

Corrigendum: Short-Interval Sequential CAR-T Cell Infusion May Enhance Prior CAR-T Cell Expansion to Augment Anti-Lymphoma Response in B-NHL

Erratum: "Lung cancer in patients with fibrosing interstitial lung diseases: an overview of current knowledge and challenges". Namrata Kewalramani, Carlos Machahua, Venerino Poletti, Jacques Cadranel, Athol U. Wells and Manuela Funke-Chambour. ERJ Open Res 2022; 8: 00115-2022

Corrigendum: Prediction of severe CRS and determination of biomarkers in B cell-acute lymphoblastic leukemia treated with CAR-T cells

Correction: ROR1-targeting switchable CAR-T cells for cancer therapy

Corrigendum to: Progress of Angiogenesis Signal Pathway and Antiangiogenic Drugs in Nasopharyngeal Carcinoma